» Articles » PMID: 32107531

Pediatric Hemophagocytic Lymphohistiocytosis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2020 Feb 29
PMID 32107531
Citations 175
Authors
Affiliations
Soon will be listed here.
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome describing patients with severe systemic hyperinflammation. Characteristic features include unremitting fever, cytopenias, hepatosplenomegaly, and elevation of typical HLH biomarkers. Patients can develop hepatitis, coagulopathy, liver failure, central nervous system involvement, multiorgan failure, and other manifestations. The syndrome has a high mortality rate. More and more, it is recognized that while HLH can be appropriately used as a broad summary diagnosis, many pediatric patients actually suffer from an expanding spectrum of genetic diseases that can be complicated by the syndrome of HLH. Classic genetic diseases in which HLH is a typical and common manifestation include pathogenic changes in familial HLH genes (PRF1, UNC13D, STXBP2, and STX11), several granule/pigment abnormality genes (RAB27A, LYST, and AP3B1), X-linked lymphoproliferative disease genes (SH2D1A and XIAP), and others such as NLRC4, CDC42, and the Epstein-Barr virus susceptibility diseases. There are many other genetic diseases in which HLH is an infrequent complication of the disorder as opposed to a prominent manifestation of the disease caused directly by the genetic defect, including other primary immune deficiencies and inborn errors of metabolism. HLH can also occur in patients with underlying rheumatologic or autoinflammatory disorders and is usually designated macrophage activation syndrome in those settings. Additionally, HLH can develop in patients during infections or malignancies without a known (or as-yet-identified) genetic predisposition. This article will attempt to summarize current concepts in the pediatric HLH field as well as offer a practical diagnostic and treatment overview.

Citing Articles

Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis.

Sun S, Liu Y, Zhao H, Miu Y, Huang X, Shen S Pediatr Res. 2025; .

PMID: 40044884 DOI: 10.1038/s41390-025-03962-w.


Salvage treatment of AOSD-associated macrophage activation syndrome with bariticinib following conventional immunosuppressive therapy.

Xu Y, Yin Y, Li W, Zhou J, Wang Y, Huang Y Clin Rheumatol. 2025; .

PMID: 39939513 DOI: 10.1007/s10067-025-07352-9.


Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis.

Canny S, Stanaway I, Holton S, Mitchem M, ORourke A, Pribitzer S Crit Care Explor. 2025; 7(2):e1203.

PMID: 39888602 PMC: 11789895. DOI: 10.1097/CCE.0000000000001203.


Hemophagocytic lymphohistiocytosis as the initial manifestation of bone marrow failure in a child with a TERC variant telomere biology disorder.

Medina-Neira D, Alvarado-Gamarra G, Huamani-Condori B, Purizaca-Rosillo N, Atamari-Anahui N, Matos-Villena E Ther Adv Rare Dis. 2025; 6():26330040241311621.

PMID: 39780848 PMC: 11705338. DOI: 10.1177/26330040241311621.


IL-18 and IL-18BP: A Unique Dyad in Health and Disease.

Novick D Int J Mol Sci. 2025; 25(24.

PMID: 39769266 PMC: 11727785. DOI: 10.3390/ijms252413505.


References
1.
Tan H, Yong Y, Andrade B, Shankar E, Ponnampalavanar S, Omar S . Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2015; 29(4):421-31. DOI: 10.1097/QAD.0000000000000557. View

2.
Karaman S, Urganci N, Kutluk G, Cetinkaya F . Niemann - Pick disease associated with hemophagocytic syndrome. Turk J Haematol. 2016; 27(4):303-7. DOI: 10.5152/tjh.2010.54. View

3.
Benson L, Li H, Henderson L, Solomon I, Soldatos A, Murphy J . Pediatric CNS-isolated hemophagocytic lymphohistiocytosis. Neurol Neuroimmunol Neuroinflamm. 2019; 6(3):e560. PMC: 6467688. DOI: 10.1212/NXI.0000000000000560. View

4.
Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M . Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017; 96(8):1241-1251. DOI: 10.1007/s00277-017-2993-y. View

5.
Zhang K, Biroschak J, Glass D, Thompson S, Finkel T, Passo M . Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008; 58(9):2892-6. PMC: 2779064. DOI: 10.1002/art.23734. View